

## CPhI Istanbul 2016

The leading pharma event in MENA and Turkey, CPhI Istanbul, returns March 8th-10th 2017 for its fourth consecutive year. Following record breaking exhibitor and attendee numbers in 2016, CPhI Istanbul 2017 stands to be a unique forum for representatives from both the local and international pharma industry.

With the show's growing success, co-located with ICSE, P-MED and Innopack, CPhI Istanbul will now take place in a new, larger venue at

the Istanbul Expo Center in 2017. As a bridge between Europe and Asia, Istanbul continues to provide an unrivalled meeting point for pharma professionals to build new partnerships and gather market insight.

With a rapidly evolving pharma economy, Turkey raises no doubt as a market with huge potential and the ideal location for such an exhibition. Having already cemented itself as a pharmaceutical hub, Turkey's pharma market already hosts nearly 90 pro-

duction facilities, 20,000 employees and direct access to the markets of the Middle East and North Africa. Set to experience the fastest growth rate in the OECD – averaging 6.7% per year from 2011-2018 – Turkey has positioned itself to emerge as a top ten global healthcare economy by 2023.

CPhI Istanbul 2017 will continue to serve as an invaluable opportunity for pharma professionals. For more information, visit: [www.cphi.com/istanbul](http://www.cphi.com/istanbul) or contact: [Karenmaguire@ubm.com](mailto:Karenmaguire@ubm.com).

Santa Farma Stc

## Santa Farma Announces New Manufacturing Facility

Santa Farma, a Turkish based pharmaceutical manufacturer, is delighted to announce that its new manufacturing facility that was inaugurated in late 2015 is now fully operational. It has recently been granted GMP from the Turkish MoH, has applied for ISO9001, ISO14001 and ISO18001 accreditation and is expecting EU GMP approval in the final quarter of 2016 and FDA auditing during the next two years. The production capabilities of the new plant include:

- Solids (film- or sugar-coated tablets and uncoated tablets)
- Effervescent
- Powder filling (bottle filling)
- Capsule Filling (able to fill powder and pellet and tablet)
- Semi Solids (gels – ointments – creams)
- Liquids (syrups – sprays)

The plant's modern systems include: BMS, Qmex, fingerprint access control, cross contamination airlocks, totally aggregated serialisation, and state-of-the-art data integrity and security. The new plant allows the consolidation of Santa Farma's production needs under one roof and is now arguably the most modern contract manufacturer in Turkey.

Ginsena Stand no 2L38

## Ginsena Introduces Serialisation Track And Trace System

Ginsena, the Swiss subsidiary of Isocho Florida International Group, is pleased to announce the introduction of a serialisation track and trace system at its fully accredited Bioggio manufacturing site. The serialisation, which future-proofs the plant toward incoming international standards, will involve both capsule and liquid lines and will be implemented by the start of 2017.

## Piramal Acquires Ash Stevens

Piramal Enterprises has acquired the US CDMO Ash Stevens via its local subsidiary in an all-cash deal for \$42.95 million plus an earn-out bonus of up to \$10 million.

Ash Stevens is based at Riverview, Michigan, where it has some 5,000 m<sup>2</sup> of facilities, eight chemical drug development and production laboratories and six full-scale production areas. These feature necessary engineering and containment controls for the safe handling and cGMP manufacture of small and large-scale high potency APIs (HPAPIs). The facility has approvals from US, EU, Australia, Japan, Korea, Mexico regulatory agencies.

The company is one of the longest-standing players in HPAPIs in the US, with experience of working with high potency oncologic and other drugs, as well as a track record of 14 manufacturing approvals (NDAs) in its 50-year history. It was HPAPIs, above all, that drove the acquisition, according to Vivek Sharma, CEO of Piramal Pharma Solutions, because about 25% of the molecules in clinical development are potent and Piramal is seeking to build a more comprehensive asset platform.

Piramal already has two facilities in North America: the Torcan facility in Toronto for complex, high value APIs and the more recently acquired and subsequently expanded Coldstream Laboratories in Kentucky for fill-finish. "We expect this acquisition to also be synergistic with our Antibody-Drug Conjugates (ADCs) and injectable business. We can now fulfil client requirements for a single source of supply for both HPAPIs and drug products," Sharma adds.

This includes the former Avacia site at Grangemouth, UK, which can carry out the conjugation of any HPAPIs at Riverview to an ADC, followed by fill-finish at Coldstream. Piramal is a leading CDMO investor in multiple capabilities related to ADCs.

Dr. Stephen Munk, chief executive officer of Ash Stevens, said, "We look forward to working with the Piramal leadership and management team, to develop API solutions that benefit customers and improve the lives of patients. The commitment that Piramal has shown towards growing its healthcare businesses, coupled with the complementary capabilities that our two firms have, makes this an exciting time for Ash Stevens and our employees."

## CPhI Russia 2016

As the Russian government continues to boost the pharma industry with its ambitious 2020 plan, what better time to benefit from the opportunities the Russian pharma market has to offer? The Russian government is investing money to attract foreign partnerships by fast-track approval processes, tax incentives and global promotion of Russian pharmaceutical manufacturing and research & development. The country is also experiencing an increasing finished dosage manufacturing capacity.

For newcomers in the Russian market, it is essential to network and create business partnerships with domestic players to gain foothold of the market. Participating in CPhI Russia & IPHEB means that you will be participating in the most all-round pharmaceutical event; the region has to offer. The event offers complimentary Forum discussions and seminars, with some of the leading pharma experts, so that you can gain in-depth knowledge about the region's market. You will also be able

to network with top-level executives via the highly acclaimed Matchmaking programme – free for all attendees of the show.

CPhI Russia & IPHEB is collocated with P-MED, to showcase the latest pharma machinery, equipment and technology, and Innopack to bring the latest innovations in packaging and drug delivery. The event brings companies in the field of ingredients, finished dosage, packaging, technology, and machinery. Learn more about the event via [www.cphi.com/russia](http://www.cphi.com/russia).

Chemistry for a Bright Future.



Learn more at Booth 1F40



APELOA 普洛  
A member of the Hengdian Group, A Public company

T: +86-571-8763 5800  
F: +86-571-8799 0222  
E: [info@hengdian-group.com](mailto:info@hengdian-group.com)

[www.hengdian-group.com](http://www.hengdian-group.com)

Hengdian Group, established in 1975, is one of the largest privately owned enterprises in China. Our main focus is creating a healthy life and future. Hengdian provides CMO services with integrated EHS management systems and products from 3 cGMP and FDA approved manufacturing sites.

- Scientific Services and Global Resources
- API and intermediates research, production and distribution
- Fluorination Experts
- Asymmetric Synthesis, Cryogenic Reactions and Heterocycles
- Trusted Global Sourcing and Dependable Sales

galenIQ™ – the bulk filler-binder.  
Great choice. Great taste.



- galenIQ™ is pharma-grade Isomalt (Ph. Eur., USP-NF, BP, JP) that makes medicine taste pleasant.
- The filler-binder with sweet sugar-like taste.
- Due to its multifunctionality your best choice excipient to be used for a broad variety of dosage forms.

Come and visit us at  
BOOTH #4L75

Our team of experts is available for your product development with galenIQ™. Please contact us: [info@galenIQ.com](mailto:info@galenIQ.com) - [www.galenIQ.com](http://www.galenIQ.com)

galenIQ™  
a brand of benes